Azurrx biopharma, inc. (AZRX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Cash flows from operating activities:
Net loss

-5,261

-1,281

-4,192

-5,042

-4,660

-4,019

-2,571

-3,309

-3,632

-2,481

-3,134

-2,671

-2,809

-5,631

-3,198

-3,770

-1,991

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

9

11

17

16

17

15

15

15

14

13

12

12

10

11

11

11

10

Amortization

131

131

131

131

561

177

181

185

191

183

164

189

166

167

174

176

171

Non-cash lease expense

6

-

-

-

1

-

-

-

-

-

-

-

-

-

-

-

-

Fair value adjustment, warrants

-

-

-

-

-

-

-

-

-

0

0

0

0

-455

-285

-1,657

69

Fair value adjustment, contingent consideration

-

-

-

-

-

30

-80

-170

10

-30

250

-260

-100

1,200

-900

0

0

Stock-based compensation

54

32

30

0

511

1,134

29

248

29

21

36

29

522

0

0

0

0

Common stock issued to settle accounts payable, amount

131

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Restricted stock granted to employees/directors

19

50

63

197

296

581

121

222

113

487

0

0

0

-

-

-

-

Restricted stock granted to consultants

87

-

22

30

60

-

140

220

0

-

3

140

81

-

0

0

0

Warrants issued to consultants

-

-

-

-

-

-

-

-

-

-

16

158

402

-

0

48

7

Accrued interest on convertible debt

164

-12

50

49

24

0

0

0

0

7

51

45

0

142

380

288

348

Accretion of debt discount

2,059

-

-

-

29

-

-

-

-

-

-

-

-

-

-

-

-

Accreted interest on debt discount - warrants

-

-

-

-

-

0

5

45

46

-

-

-

-

117

310

93

362

Warrant modification

-

-

-

-

-

-

0

0

428

-

-

-

-

-

-

-

-

Changes in assets and liabilities, net of effects of acquisition:
Other receivables

2,064

-487

-68

-43

-149

-2,053

-127

-127

120

-858

790

103

-32

-776

131

731

45

Prepaid expenses

87

-505

107

139

172

-459

73

82

59

-208

158

-15

22

398

-459

-132

-36

Right of use assets

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Deposits

0

-

0

0

-4

-

0

-15

0

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

-832

-1,021

-339

425

514

1,313

-607

-387

423

-349

499

-755

371

-155

214

235

511

Interest payable

-

-

-

-

-

0

-7

0

0

-

-

-

-

0

0

2

2

Net cash used in operating activities

-1,291

-3,225

-4,153

-4,025

-2,627

-3,340

-2,666

-2,648

-2,214

-2,469

-1,293

-2,257

-1,165

-2,016

-1,226

-655

-636

Cash flows from investing activities:
Purchase of property and equipment

4

-17

3

-0

13

201

7

11

29

-31

10

20

0

-0

1

10

0

Net cash used in investing activities

-4

-6

-3

0

-13

-257

-7

-11

-29

-0

-10

-20

-0

0

-1

-10

-0

Cash flows from financing activities:
Proceeds issuances of common stock, net

144

-

4,468

5,023

0

-

0

9,577

2,324

-

364

4,645

0

-

-

-

-

Proceeds issuances of convertible debt, net

3,227

2,967

0

0

2,000

0

0

0

0

-

-

-

-

0

0

1,869

225

Received from stockholder in relation to warrant modification

0

-

0

0

-61

-

0

0

0

-

-

-

-

-

-

-

-

Repayments of convertible debt

450

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Repayments of notes payable

164

54

64

95

94

31

26

53

79

137

26

51

77

76

0

0

0

Net cash provided by financing activities

2,756

1,846

4,403

4,928

1,967

255

-313

9,524

2,245

159

337

5,593

-77

3,652

0

1,869

225

Increase (decrease) in cash

1,460

-1,395

245

902

-674

-3,342

-2,986

6,865

1

-2,310

-965

3,315

-1,243

1,636

-1,227

1,202

-412

Effect of exchange rate changes on cash

-6

12

-6

-5

-26

29

-5

-19

-0

-62

83

-19

1

8

1

-17

-0

Supplemental disclosures of cash flow information:
Cash paid for interest

104

-

0

1

3

-

0

0

1

-

0

0

0

-

-

-

-

Cash paid for income taxes

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

1

0

0

0

Cash paid for taxes

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

Non-cash investing and financing activities:
Convertible debt converted into common stock, Amount

-

-

-

-

-

-

0

0

68

-

-

-

-

-

-

-

-

Conversion of preferred shares into common shares by Protea

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,764

1,715

Conversion of convertible debt into common shares

-

-

-

-

-

-

-

-

-

-

717

0

0

-

-

-

-

Common stock issued Mayoly for patents, Amount

0

-1,740

0

0

1,740

1,300

0

0

0

-

-

-

-

-

-

-

-

Warrant modification related to convertible debt issuance

0

-

0

0

325

-

-

-

-

-

-

-

-

-

-

-

-